Century Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Century Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$503K	Buy	+11,665	New	+$415K	0.09%	199

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Century Capital Management's SUPN Position: Q2 2017 in Review

Century Capital Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2017: 11,665 shares worth $503K. The stake represents 0.09% of the portfolio and ranks #199 among its holdings.

266 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

Century Capital Management held 11,665 shares of Supernus Pharmaceuticals worth $503K as of Q2 2017.
Supernus Pharmaceuticals was a new Century Capital Management position in Q2 2017.
Supernus Pharmaceuticals made up 0.09% of Century Capital Management's portfolio in Q2 2017, its #199 holding.
266 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Century Capital Management's 13F filing for Q2 2017, filed 10 Aug 2017.